The cost of Prolia injections can vary significantly based on insurance coverage, geographic location, and whether the medication is obtained through a doctor's office, clinic, or specialty pharmacy. Without insurance, the list price for a single 60mg prefilled syringe of Prolia can range from several hundred to over a thousand dollars.
What factors influence the price of Prolia?
Several factors contribute to the overall cost of Prolia. Insurance plans often have different formularies and tiers, which determine the patient's out-of-pocket expense through copays or coinsurance. Patient assistance programs offered by the manufacturer, Amgen, may help reduce costs for eligible individuals who meet certain financial criteria [1]. Additionally, the site of administration, such as a hospital outpatient department versus a physician's office, can impact the billed amount due to different overhead costs [2].
How much does Prolia cost with different insurance plans?
With commercial insurance, a patient's out-of-pocket cost for Prolia typically involves a copay, which can range from a flat fee to a percentage of the drug's cost. Medicare Part B covers Prolia for its approved indications, and beneficiaries usually pay a coinsurance, which is a percentage of the Medicare-approved amount. For individuals with Medicare Advantage plans, copays and coinsurance may differ. Medicaid coverage also varies by state [2]. It is advisable for patients to verify their specific coverage details with their insurance provider.
Are there patient assistance programs for Prolia?
Yes, Amgen offers the Prolia Savings Program, which can provide eligible commercially insured patients with savings on their Prolia prescription. This program aims to make the medication more affordable for those who qualify [1]. Information regarding eligibility and enrollment can typically be found on the Prolia website or by speaking with a healthcare provider's office.
When does Prolia's patent expire?
The primary patents for Prolia (denosumab) have expiration dates that vary. DrugPatentWatch.com tracks these patent expirations, which are crucial for determining when generic or biosimilar versions of the drug might become available. The key patents protecting Prolia are expected to expire at different times, with some expiring in the mid-to-late 2020s [3]. Understanding these patent timelines is important for anticipating future market competition and potential cost reductions.
Can biosimilars for Prolia become available?
The development of biosimilars for biologics like Prolia is a complex process governed by regulatory pathways. Once the relevant patents expire and regulatory approvals are obtained, biosimilar versions of denosumab could enter the market. Biosimilars are approved by regulatory agencies to be highly similar to an existing biologic, with no clinically meaningful differences in terms of safety, purity, and potency. The introduction of biosimilars can often lead to increased competition and potentially lower prices for patients [4].
What are the alternatives to Prolia?
Several alternative treatments exist for conditions treated by Prolia, such as osteoporosis and bone loss associated with certain cancer therapies. These alternatives include other bisphosphonates (e.g., alendronate, risedronate, zoledronic acid), teriparatide, abaloparatide, and romosozumab. The choice of alternative depends on the patient's specific condition, medical history, risk factors, and response to previous treatments [5].
***
Sources:
[1] https://www.prolia.com/savings-support
[2] https://www.drugpatentwatch.com/drugs/prolia/
[3] https://www.drugpatentwatch.com/drugs/prolia/
[4] https://www.fda.gov/drugs/biosimilars/questions-and-answers-biosimilars
[5] https://www.drugpatentwatch.com/drugs/prolia/